We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

44 hedge funds and large institutions have $3.55M invested in Lisata Therapeutics in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 47 → 44 (-3)

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

42% less capital invested

Capital invested by funds: $6.13M → $3.55M (-$2.58M)

75% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 16

Holders
44
Holders Change
-3
Holders Change %
-6.38%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
16
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$109K
2
RJA
Raymond James & Associates
Florida
+$42.3K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$33.8K
4
Citadel Advisors
Citadel Advisors
Florida
+$20.1K
5
CI
Cowen Inc
New York
+$14.7K

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$353K
2
Millennium Management
Millennium Management
New York
-$214K
3
Wells Fargo
Wells Fargo
California
-$46K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$45.3K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$34K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$4K – – –
Deutsche Bank
27
Deutsche Bank
Germany
$4K – – –
Morgan Stanley
28
Morgan Stanley
New York
$2K -$2.65K -27 -64%
Citigroup
29
Citigroup
New York
$2K +$98 +1 +5%
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$1K -$6.68K -68 -91%
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$1K – – –
Group One Trading
32
Group One Trading
Illinois
$1K – – –
JIC
33
Joel Isaacson & Co
New York
$1K – – –
LTFS
34
Ladenburg Thalmann Financial Services
Florida
$1K – – –
DOA
35
D'Orazio & Associates
Virginia
$1K +$1.67K +17 New
Geode Capital Management
36
Geode Capital Management
Massachusetts
$219 -$98 -1 -0.1%
Millennium Management
37
Millennium Management
New York
– -$214K -1,319 Closed
Wells Fargo
38
Wells Fargo
California
– -$46K -468 -100%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
– -$34K -208 Closed
CG
40
Caprock Group
Idaho
– -$22K -136 Closed
MLM
41
Mount Lucas Management
Pennsylvania
– -$16K -97 Closed
Simplex Trading
42
Simplex Trading
Illinois
– -$5K -33 Closed
IWMPD
43
Integrated Wealth Management (Palm Desert)
California
– -$4K -26 Closed
Creative Planning
44
Creative Planning
Kansas
– -$983 -10 -77%
IA
45
IFP Advisors
Florida
– -$491 -5 Closed
TRCT
46
Tower Research Capital (TRC)
New York
– -$1K -4 Closed
CI
47
Cowen Inc
New York
– +$14.7K +150 New
1
2

LSTA Hedge Fund Activity: Q1 2016 in Review

44 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2016, worth a combined $3.55M — down 42% from $6.13M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of LSTA and 6 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 4 added.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $109K. The largest seller was Great Point Partners, cutting an estimated $353K.

  • 44 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2016, down from 47 in Q4 2015.
  • Funds reported $3.55M of Lisata Therapeutics stock for Q1 2016, down 42% quarter-over-quarter.
  • 6 funds opened new Lisata Therapeutics positions in Q1 2016 and 9 closed out, a net change of -3 holders.
  • The largest Lisata Therapeutics buyer in Q1 2016 was Jacobs Levy Equity Management, an estimated $109K added.
  • The largest Lisata Therapeutics seller in Q1 2016 was Great Point Partners, an estimated $353K sold.

Based on aggregated 13F filings for Q1 2016.